Pharming Group NV ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY Revenue (est.)
$382.8Mnext fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release and Conference Call | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Total Revenue Quarterly376.1MTarget: 405000000 to 425000000
Joenja (leniolisib) Revenue Quarterly14.1MTarget: Accelerating growth driven by global launches
RUCONEST Revenue Quarterly58.4MTarget: Mid-single-digit growth in the US
Watch Items
- FDA Pediatric sNDA Approval for Joenja (leniolisib) in children aged 4 to 11Trigger: PDUFA target action date of October 24, 2026Action: Monitor FDA regulatory updates and prepare commercial launch plans for the pediatric demographic.
- RUCONEST competitive pressure and inventory drawdownsTrigger: Revenue decline exceeding 15% year-over-yearAction: Assess market share dynamics in the hereditary angioedema (HAE) space and optimize US commercial execution.
- Transition of external auditor to KPMG N.V. and internal control remediationTrigger: Completion of the FY 2026 audit and assessment of material weaknessesAction: Review audit committee reports and progress on internal control over financial reporting (ICFR) remediation.
Research as of 19 Jun 2026